Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Paris: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a ...

Sanofi’s acquisition of Vigil Neuroscience involves purchasing the company for $8 per share in cash, along with an additional $2 in contingent value rights, pending the commercial success of ...

May 22, 2025 Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million ...

Japan’s Nippon Steel is set to finalize its acquisition of U.S. Steel for $55 per share, following a green light from ...

In its most recent quarter, Nvidia delivered blockbuster results, driven by full-scale production of its Blackwell GPUs and ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €110.00. The company’s shares closed yesterda ...

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia ...

The latest price target for Vigil Neuroscience (NASDAQ:VIGL) was reported by JMP Securities on May 22, 2025. The analyst firm set a price target for $0.00 expecting VIGL to fall to within 12 ...

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €120.00. The company’s sh ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...